Artículos por temáticas

Novel action of metformin in the prevention of haloperidol-induced catalepsy in mice: Potential in the treatment of Parkinson's disease?

Adeyemi OO, Ishola IO, Adedeji HA.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Oct 24. pii: S0278-5846(13)00235-2. doi: 10.1016/j.pnpbp.2013.10.014. [Epub ahead of print]

Medication reminder service for mobile phones: an open feasibility study in patients with Parkinson's disease.

Keränen T, Liikkanen S.

Telemed J E Health. 2013 Nov;19(11):888-90. doi: 10.1089/tmj.2013.0014.

Oxidative stress mechanisms underlying Parkinson's disease-associated neurodegeneration in C. elegans.

Chakraborty S, Bornhorst J, Nguyen TT, Aschner M.

Int J Mol Sci. 2013 Nov 21;14(11):23103-28. doi: 10.3390/ijms141123103. Review.

Effectiveness of BoNT A in Parkinson's disease upper limb tremor management.

Rahimi F, Bee C, Debicki D, Roberts AC, Bapat P, Jog M.

Can J Neurol Sci. 2013 Sep;40(5):663-9.

A controlled clinical trial investigating the effects of cycle ergometry training on exercise tolerance, balance and quality of life in patients with Parkinson's disease.

Lauhoff P, Murphy N, Doherty C, Horgan NF.

Disabil Rehabil. 2013 Mar;35(5):382-7. doi: 10.3109/09638288.2012.694962.

Is neuroinflammation involved in the development of dementia in patients with Parkinson's disease?

Song IU, Kim YD, Cho HJ, Chung SW.

Intern Med. 2013;52(16):1787-92.

The diagnosis of myocardial infarction in the Wolff-Parkinson-White syndrome.

Liu R, Chang Q.

Int J Cardiol. 2013 Aug 10;167(3):1083-4. doi: 10.1016/j.ijcard.2012.10.055. Review. No abstract available.

Treatment of patients with early and advanced Parkinson's disease with rotigotine transdermal system: age-relationship to safety and tolerability.

Oertel W, LeWitt P, Giladi N, Ghys L, Grieger F, Boroojerdi B.

Parkinsonism Relat Disord. 2013 Jan;19(1):37-42. doi: 10.1016/j.parkreldis.2012.06.009.

The spectrum of nonmotor symptoms in early Parkinson disease.

Khoo TK, Yarnall AJ, Duncan GW, Coleman S, O'Brien JT, Brooks DJ, Barker RA, Burn DJ.

Neurology. 2013 Jan 15;80(3):276-81. doi: 10.1212/WNL.0b013e31827deb74.

Neuropsychiatric symptoms in Nigerian patients with Parkinson's disease.

Ojagbemi AA, Akinyemi RO, Baiyewu O.

Acta Neurol Scand. 2013 Jul;128(1):9-16. doi: 10.1111/ane.12062.

Brain volumetry in Parkinson's disease with and without dementia: where are the differences?

Lee SH, Kim SS, Tae WS, Lee SY, Lee KU, Jhoo J.

Acta Radiol. 2013 Jun;54(5):581-6. doi: 10.1177/0284185113476029.

[The prevalence of Parkinson's disease, associated dementia, and depression in Dresden].

Riedel O, Schneider C, Klotsche J, Reichmann H, Storch A, Wittchen HU.

Fortschr Neurol Psychiatr. 2013 Feb;81(2):81-7. doi: 10.1055/s-0032-1330278. German.

Bilateral stimulation of the subthalamic nucleus has differential effects on reactive and proactive inhibition and conflict-induced slowing in Parkinson's disease.

Obeso I, Wilkinson L, Rodríguez-Oroz MC, Obeso JA, Jahanshahi M.

Exp Brain Res. 2013 May;226(3):451-62. doi: 10.1007/s00221-013-3457-9.

Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations.

Chahine LM, Qiang J, Ashbridge E, Minger J, Yearout D, Horn S, Colcher A, Hurtig HI, Lee VM, Van Deerlin VM, Leverenz JB, Siderowf AD, Trojanowski JQ, Zabetian CP, Chen-Plotkin A.

JAMA Neurol. 2013 Jul;70(7):852-8. doi: 10.1001/jamaneurol.2013.1274.